Two replicate , double-blind , randomized , 12-week studies ( ANHELTO 1 [ NCT01694771 ] and ANHELTO 2 [ NCT01696058 ] ) evaluated the efficacy and safety of olodaterol 5 g once daily ( via Respimat ( ) ) combined with tiotropium 18 g once daily ( via HandiHaler ( ) ) versus tiotropium 18 g once daily ( via HandiHaler ( ) ) combined with placebo ( via Respimat ( ) ) in patients with moderate to severe COPD .